ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ARS Pharmaceuticals, Inc. NASDAQ:SPRY Healthcare · Biotechnology
Mkt Cap $336.13M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
8-K 8-K/A 10-K 10-Q 10-Q/A S-1 S-1/A S-3 S-3ASR S-8 DEF 14A DEFA14A DEFM14A 3 3/A 4 4/A 13D 13D/A 13G 13G/A 144 424B4 D D/A UPLOAD CORRESP
Form Description Filed Links 144 Notice of Proposed Sale of Securities
10/30/26 Oct 30, 2026 144 Notice of Proposed Sale of Securities
10/19/26 Oct 19, 2026 4 Statement of Changes in Beneficial Ownership
10/5/26 Oct 5, 2026 144 Notice of Proposed Sale of Securities
10/1/26 Oct 1, 2026 144 Notice of Proposed Sale of Securities
9/30/26 Sep 30, 2026 144 Notice of Proposed Sale of Securities
9/11/26 Sep 11, 2026 144 Notice of Proposed Sale of Securities
9/11/26 Sep 11, 2026 144 Notice of Proposed Sale of Securities
9/4/26 Sep 4, 2026 144 Notice of Proposed Sale of Securities
9/3/26 Sep 3, 2026 4 Statement of Changes in Beneficial Ownership
9/2/26 Sep 2, 2026 144 Notice of Proposed Sale of Securities
9/2/26 Sep 2, 2026 144 Notice of Proposed Sale of Securities
9/1/26 Sep 1, 2026 144 Notice of Proposed Sale of Securities
8/31/26 Aug 31, 2026 144 Notice of Proposed Sale of Securities
8/20/26 Aug 20, 2026 144 Notice of Proposed Sale of Securities
8/20/26 Aug 20, 2026 144 Notice of Proposed Sale of Securities
8/19/26 Aug 19, 2026 144 Notice of Proposed Sale of Securities
8/19/26 Aug 19, 2026 144 Notice of Proposed Sale of Securities
8/18/26 Aug 18, 2026 144 Notice of Proposed Sale of Securities
8/18/26 Aug 18, 2026 3 Initial Statement of Beneficial Ownership
8/17/26 Aug 17, 2026 10-Q 8/13/26 Aug 13, 2026 8-K 8/13/26 Aug 13, 2026 13G Beneficial Ownership Report
7/27/26 Jul 27, 2026 8-K 7/17/26 Jul 17, 2026 13G/A Beneficial Ownership Report (Amended)
7/14/26 Jul 14, 2026
